哮喘联盟

   摘要
   促使我们去完善哮喘治疗方式和药物配送系统的动力强大，但是在本综述中我们提出这样的疑问：这是否总是正确的？我们选择反对的一方，即认为完善药物治疗方式并不总是必需的，真正需要的是进一步了解疾病的生物学原理。这里我们选择哮喘和支气管扩张剂中的β2受体激动剂，以展示一系列治疗是怎样发展和持续完善的。本综述中我们预设病毒所致哮喘发作是肺部损伤的最大原因，且在关键时刻需要用β2受体激动剂进行治疗。我们探讨了β2受体激动剂治疗病毒所致哮喘发作失败的原因，并解释为什么进一步设计的β2受体激动剂疗法治疗哮喘人群仍会失败。我们反溯疾病发生的潜在生物学机制，以证明这一观点，强调还需“更多研究”为哮喘患者寻找替代疗法。
 

（苏楠 审校）
Curr Drug Deliv.2014 Jun 6. [Epub ahead of print]

 

Do We Really Need to Keep Redesigning β2-Agonists for the Management of Asthma?
 

Van Ly D, Oliver BG1.
 

Abstract
There is an enormous drive to refine therapeutic designs and delivery systems, but in this review we ask if this is always the right direction? We choose to play devil's advocate, and argue that refining drug design is not always needed, and what is actually needed is a greater understanding of the biology of the disease. Here we focus on asthma and the β2-agonist group of bronchodilators as an example of how a class of therapeutic has been developed and continues to be developmentally refined. In this review we define viral-induced exacerbations as the greatest cause of lung attacks and the most crucial time β2-agonist therapy is needed. We explore the reasons why β2-agonist therapy fails in patients with rhinovirus-induced exacerbations, and explain why further "engineered" β2-agonist therapies is likely to continue to fail in this subset of asthmatic population. We justify our perspective by returning to the biology that underlies the cause of disease and highlight the need for "more research" into alternative therapies for this population of asthmatic patients.
 

Curr Drug Deliv.2014 Jun 6. [Epub ahead of print]